TASCENSO ODT® (fingolimod)

As unique as your patients.

The same proven fingolimod you know, with an individualized support program.

TASCENSO ODT comes in a unique orally disintegrating tablet formulation.1 It is accompanied by Cycle Vita, our support platform dedicated to providing support to all your eligible* patients. Including in-home first dose observations, financial assistance and a Bridge Program.

 

Heart Fingerprint

Unique | Support

Tascenso Care Icon

Support

Read more about our dedicated hub support program, Cycle Vita.

Tascenso Dissolve Icon

Product

Find out more about the orally disintegrating tablet, including how it can be taken.

Graph Icon

Efficacy and Safety

See the efficacy and safety data, and learn more about its bioequivalence.

Enroll Icon

Enroll

Download the enrollment form to enroll your patients on TASCENSO ODT.

Tascenso Dissolve Icon

Product

TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet formulation.1

  • Unique orally disintegrating tablet for MS treatment
  • Same proven fingolimod
  • Same efficacy & safety as Gilenya®**
  • Not a generic²
  • Not substitutable at the pharmacy level²
  • Dissolves on the tongue in seconds
  • Once daily, with or without food, with or without water
  • Available as 0.25 mg and 0.5 mg orally disintegrating tablets
Find out more
Tascenso Care Icon

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated hub support program, which delivers individualized product support* at every step. Including:

  • TASCENSO Time Program (in-home baseline assessments and first dose observation)
  • Financial assistance (including $0 co-pay)
  • Bridge Program
  • Medication Adherence Support
Find out more
Cycle Pharma Logo

References

1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.

2. FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed April 25th 2023. Available: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

* Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

** Gilenya® is a registered trademark of Novartis AG.